FDA Grants Fast Track Designation to Pfizer's DMD Gene Therapy

Pfizer snagged Fast Track designation from the U.S. Food and Drug Administration (FDA) for its Duchenne muscular dystrophy (DMD) gene therapy treatment, PF-06939926.